🇺🇸 FDA
Patent

US 12274747

Compositions and methods for treating cytokine release syndrome

granted A61KA61K35/17A61K38/1774

Quick answer

US patent 12274747 (Compositions and methods for treating cytokine release syndrome) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K35/17, A61K38/1774, A61K39/3955, A61K39/39558